Breast Augmentation Surgery — Cost, Top Hospitals & Success Rates | MyMedicPlus

Breast augmentation (augmentation mammaplasty) is the surgical placement of a breast implant — or injection of autologous fat — to increase the size, improve the shape, or restore volume to the breast. It is consistently among the top three most commonly performed cosmetic surgical procedures globally, with approximately 1.8 million procedures performed annually worldwide (ISAPS 2023). The operation typically takes 1-2 hours under general anaesthesia and involves creating a pocket in the breast tissue or beneath the pectoral muscle, placing the selected implant, and closing the incision.

Modern breast implants consist of a silicone elastomer outer shell filled with either cohesive silicone gel (the vast majority today) or saline solution. Fifth-generation cohesive gel implants — 'form-stable' or 'gummy bear' implants — maintain their shape even if the shell were cut, reducing the consequence of shell rupture. Implant choices involve decisions about size (volume in cc), shape (round vs anatomical/teardrop), surface texture (smooth vs textured vs polyurethane-coated), and profile (low to extra-high projection). These decisions are made collaboratively between patient and surgeon using sizers, 3D imaging systems, and the 'desired bra cup' goal as an approximate guide.

The surgical approach involves four interrelated decisions: implant type, implant size, incision site, and pocket plane. Incision options include inframammary (in the fold under the breast — most common, most direct access, lowest complication rate), periareolar (around the lower areola), transaxillary (through the axilla — no breast scar), and transumbilical (TUBA — saline implants only, through the navel). Pocket planes range from subglandular (above the pectoral muscle, more natural position, more prone to capsular contracture) to total submuscular (beneath the entire pectoral muscle, reduces mammography interference, higher rate of implant animation with muscle movement) to the most commonly used dual-plane — behind the muscle for the upper two-thirds and subglandular for the lower third.

Breast augmentation is performed at accredited surgical facilities by board-certified plastic surgeons. Pre-operative assessment includes breast examination, baseline mammography or ultrasound in appropriate age groups, and photographic documentation for surgical planning.

Breast augmentation is primarily an elective cosmetic procedure for women with hypomastia (naturally small breasts) who desire increased breast volume, improved breast shape and projection, and greater clothing and swimwear options. It addresses significant breast asymmetry where one breast is substantially smaller than the other — a common indication where different implant sizes are used bilaterally. Volume loss after pregnancy, breastfeeding, or weight loss (post-partum breast involution) is another common presentation, where the breast envelope becomes deflated despite adequate skin.

Augmentation is also performed as part of gender-affirming surgery for trans women, in whom breast development on hormone therapy may be insufficient to meet psychological and social goals. Reconstruction of the breast mound following mastectomy for breast cancer is a related but distinct procedure typically using tissue expanders followed by permanent implants or autologous tissue flaps, and represents a reconstructive rather than cosmetic indication. Tuberous breast deformity — a congenital condition with restricted breast base and herniation of the nipple-areola complex — requires combined augmentation with radial scoring of the breast parenchyma and often areola reduction for correction.

Ideal candidates are women aged 18 or older (FDA approval for silicone implants in the USA is 22 years; 18 years for saline), with a stable body weight, in good general health, with realistic goals for a natural-appearing proportionate increase in breast size or correction of asymmetry. Patients should not be pregnant or breastfeeding. Baseline mammographic or ultrasound imaging is recommended for women over 40 and those with a family history of breast cancer, to establish a pre-operative baseline and exclude occult pathology.

Contraindications include active infection, existing undiagnosed breast pathology, unrealistic size expectations (desiring a result that would require an implant disproportionate to the patient's frame), active smoking within 4-6 weeks of surgery (impairs wound healing), significant ptosis (where augmentation alone without mastopexy would create a 'rock in a sock' appearance), autoimmune connective tissue diseases (relative contraindication due to theorised increased risk of capsular contracture and systemic symptoms), and body dysmorphic disorder. Patients on anticoagulants or antiplatelet agents require perioperative medication management.

Silicone cohesive gel implants are the global standard for breast augmentation, offering natural feel, shape stability, and long clinical track records. In the USA, FDA-approved brands include Allergan Natrelle (Inspira), Mentor MemoryGel, and Sientra. Round smooth implants are the most commonly placed globally — they provide consistent results regardless of rotation and are available across a wide size range. Anatomical (teardrop) implants create a more naturalistic slope with greater lower pole projection, particularly valued for patients with minimal existing tissue, but must be placed with textured shells to prevent rotation — textured implants have been implicated in BIA-ALCL (breast implant-associated anaplastic large cell lymphoma).

The dual-plane technique (pocket behind the muscle superiorly, in front of the muscle inferiorly) has become the most widely preferred placement for most augmentation cases — it provides natural-appearing upper pole fullness, good lower pole definition, and reduces capsular contracture rates compared to subglandular placement. Motiva Ergonomix implants (silicone gel that flows more freely within the shell) and Ideal Implants (structured saline with internal shell baffles for more natural feel) represent newer alternatives for patients wishing to avoid cohesive gel. Autologous fat transfer (lipofilling) for modest augmentation (typically half to one cup size) offers a completely natural option without implant risks, suitable for patients who have sufficient donor fat and prefer a subtle result.

Breast augmentation consistently produces high patient satisfaction rates across all published series — a 2019 systematic review in Plastic and Reconstructive Surgery reported 85-95% satisfaction rates at five years when appropriate patient selection and implant choice are made. Patients report improved self-confidence, enhanced body image, greater clothing and swimwear options, and satisfaction with the femininity of their appearance. For women with significant asymmetry, the psychological impact of correction is particularly marked.

On validated patient-reported outcome measures (BREAST-Q), scores for psychosocial wellbeing, sexual wellbeing, and physical wellbeing all demonstrate significant improvement following breast augmentation. These improvements are maintained at three and five years post-operatively in prospective cohort studies. Augmentation combined with mastopexy (breast lift) in patients with ptosis additionally restores the youthful position of the nipple-areola complex, with very high combined satisfaction rates when both components are appropriately planned.

Capsular contracture — the formation of a thick, hardened fibrous capsule around the implant causing breast hardness, pain, and distortion — is the most common long-term complication, affecting 5-10% of augmented breasts at ten years (Baker Grade III-IV requiring surgical intervention). Risk is higher with subglandular placement, textured implants, haematoma formation, subclinical biofilm infection, and radiation therapy. Implant rupture occurs in approximately 10-15% of silicone implants at ten years — 'silent rupture' (gel remains within the fibrous capsule) detected only on MRI; FDA recommends surveillance MRI at 5-6 years after silicone implant placement and then every 2-3 years.

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare but serious lymphoma arising from the fibrous capsule around textured implants — estimated at 1:2,800-86,000 (depending on implant type), with textured macro-surface implants carrying the highest risk. BIA-ALCL presents as late seroma (fluid accumulation at 6+ months post-operatively) and is treated by surgical removal of the implant and surrounding capsule. Most cases are curable with surgery alone when caught early. Breast implant illness (BII) — a constellation of systemic symptoms (fatigue, cognitive fog, joint pain, rash) attributed by patients to implants — is an emerging patient-reported phenomenon under active investigation; it has not been definitively established as an immunological disease entity but many patients report symptom improvement after en bloc explantation.

Most patients return home on the day of surgery or the following morning. Discomfort peaks at 24-48 hours, particularly with submuscular placement where the pectoral muscle adjustment causes chest tightness. A surgical bra is worn for 2-4 weeks. Light activities resume at 5-7 days; desk work at 1-2 weeks. Strenuous upper body exercise is avoided for 4-6 weeks. Implants initially appear high on the chest and settle gradually into the pocket over 3-6 months as the overlying muscle and tissue stretches and relaxes.

FDA recommendations for silicone implant surveillance include imaging assessment for silent rupture at 5-6 years after placement, then every 2-3 years — MRI is the most sensitive; contrast-enhanced ultrasound is an alternative. Regular breast self-examination and annual clinical examination are maintained alongside standard breast cancer screening protocols (mammography from age 40-50 depending on guidelines and individual risk). Patients with implants undergoing mammography should inform the radiographer so that Eklund displacement views can be obtained to visualise the full breast tissue. Follow-up at one week, six weeks, three months, and one year is standard, with ongoing annual review thereafter.

Breast augmentation costs in the USA range from USD 6,000-12,000 (surgeon fee, anaesthesia, facility, implant cost of USD 1,000-2,000 per implant) depending on implant type, technique, and geographic location. In the UK, private breast augmentation costs GBP 4,500-8,000. Premium anatomical or shaped implants and advanced techniques (dual-plane, high-definition fat grafting) cost more. Combined augmentation with mastopexy adds significantly to cost.

Turkey is Europe's most popular breast augmentation destination, with comprehensive packages (surgery, 2-3 nights hospital, transfers, compression bra, post-op care during stay) at USD 3,000-5,500 — savings of 40-60% versus UK prices. Thailand offers USD 4,000-7,000 for comparable quality at JCI-accredited hospitals with internationally trained surgeons. India offers the lowest cost (USD 2,000-4,000) with excellent surgeon quality at accredited centres. All major implant brands (Allergan, Mentor, Sientra, Motiva) are available at top international centres. MyMedicPlus connects patients with verified plastic surgeons and transparent pricing at trusted international centres.

Autologous fat transfer (lipofilling) to the breasts provides a natural augmentation of approximately half to one cup size using the patient's own harvested and processed fat, eliminating implant-related risks. It is appropriate for patients seeking subtle augmentation who have adequate donor fat. Multiple sessions may be needed as fat reabsorption of 30-50% occurs in the first three months. Non-surgical 'breast augmentation' devices — vacuum suction devices (Brava system) used daily to stimulate breast tissue growth — have modest evidence for small increases in volume when used consistently for 10 weeks; results are significantly less than surgery.

Push-up bras, breast-enhancing swimwear, and shapewear provide non-invasive options for women who do not wish surgery. For ptosis without volume deficiency, mastopexy (breast lift) alone may achieve the youthful shape a patient desires without requiring an implant. For gender dysphoria, hormone therapy alone may produce sufficient breast development in some trans women; the adequacy of this development depends on the individual's sensitivity to oestrogen.